Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

BACKGROUND: The Canadian coronavirus disease 2019 (COVID-19) immunization strategy deferred second doses and allowed mixed schedules. We compared 2-dose vaccine effectiveness (VE) by vaccine type (mRNA and/or ChAdOx1), interval between doses, and time since second dose in 2 of Canada’s larger provin...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Febriani, Yossi, Ouakki, Manale, Setayeshgar, Solmaz, El Adam, Shiraz, Zou, Macy, Talbot, Denis, Prystajecky, Natalie, Tyson, John R, Gilca, Rodica, Brousseau, Nicholas, Deceuninck, Geneviève, Galanis, Eleni, Fjell, Chris D, Sbihi, Hind, Fortin, Elise, Barkati, Sapha, Sauvageau, Chantal, Naus, Monika, Patrick, David M, Henry, Bonnie, Hoang, Linda M N, De Wals, Philippe, Garenc, Christophe, Carignan, Alex, Drolet, Mélanie, Jassem, Agatha N, Sadarangani, Manish, Brisson, Marc, Krajden, Mel, De Serres, Gaston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047203/
https://www.ncbi.nlm.nih.gov/pubmed/35438175
http://dx.doi.org/10.1093/cid/ciac290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047203/
https://www.ncbi.nlm.nih.gov/pubmed/35438175
http://dx.doi.org/10.1093/cid/ciac290

Ejemplares similares